<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2008</study_start_year><condition>Colon Cancer</condition><condition>Colorectal Neoplasms</condition><condition>Rectal Cancer</condition><condition>Anal Cancer</condition><condition>Anus Neoplasms</condition><disease>Colon Cancer</disease><disease>Colorectal Neoplasms</disease><disease>Rectal Cancer</disease><disease>Anal Cancer</disease><disease>Anus Neoplasms</disease><study_type>Observational</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2054111</full_dataset_link><location>United States</location><study_start_month>2</study_start_month><keyword>Bevacizumab</keyword><repository>ECRIN MDR</repository><study_status>Completed</study_status></additional><is_claimable>false</is_claimable><name>Avastin/[18-F]-5-fluorouracil PET/CT Imaging Feasibility Project</name><description>To determine whether using a radiolabelled analog of 5-FU, [18F]-5-fluorouracil, for PET/CT imaging can visually demonstrate differential chemotherapy delivery to known tumor sites before and after administration of bevacizumab and determine the optimal timing of bevacizumab administration to maximize the chemotherapy delivery into the tumor for improved cancer treatment.</description><dates><creation>2008-02-15</creation></dates><accession>2054111</accession><cross_references><ClinicalTrials___gov>NCT00661154</ClinicalTrials___gov></cross_references></HashMap>